Anna Hendricksen held her breath and spent hours in suspended hope as pediatric neurologist Randal Richardson, MD, and his team assessed her daughter, Annika, to determine if she met the criteria to participate in the clinical trial for Spinraza ™, also called nusinersen, a drug to treat spinal muscular atrophy (SMA).